

CombiSep, Inc.

2711 South Loop Drive
Suite 4200
Ames, IA 50010 USA
www.combisep.com

News Release

For Immediate Release

For further information, please contact Joni O'Rourke by phone at (515) 294-1690, or by e-mail at joni.orourke@combisep.com.

CombiSep Introduces the *Oligo PRO™* System

(Ames, IA September 27, 2006) CombiSep is proud to announce the introduction of the *Oligo PRO™* system, a rapid solution for performing DNA and RNA oligonucleotide purity analysis. The *Oligo PRO™* is the second in the CombiSep PRO Series of dedicated analyzer systems for the pharmaceutical and life science industries.

According to Frost & Sullivan, the total global oligonucleotide market is estimated to be \$500 million with predicted strong growth to \$776 million by 2010. The strong influence of oligonucleotide purity on numerous applications has facilitated the need for high quality, synthetic oligonucleotides subjected to comprehensive quality control procedures.

The *Oligo PRO™* system provides a rapid, cost effective and accurate method for DNA or RNA oligonucleotide purity analysis with high sample throughput and automation. The relative purity of 96 different samples is obtained in parallel using capillary gel electrophoresis with UV absorbance detection. Fully integrated software with predefined methods and advanced data analysis capabilities provide extraordinary system ease-of-use. A full line of reagents provide a complete solution for oligonucleotide purity analysis.

“The launch of the *Oligo PRO™* system furthers our efforts to provide innovative, total package solutions for scientists in the pharmaceutical and life science sectors”, says Dr. Jeremy Kenseth, CombiSep’s Marketing and Applications Manager. “The *Oligo PRO™* system provides an efficient means for characterizing oligonucleotide purity, which is critical for scientists engaged in oligo-based research to know in order to achieve high quality and reproducible results.”

About CombiSep, Inc.

Based in Iowa, CombiSep, Inc. provides innovative solutions to accelerate pharmaceutical and life sciences research. CombiSep’s core technology enables researchers to analyze up to 96 samples in parallel by capillary electrophoresis with UV absorbance detection. Dedicated analyzers are available for performing

physicochemical profiling of drug compound pK_a and log P values (*pK_a Analyzer PRO™*) and for performing DNA/RNA oligonucleotide purity analysis (*Oligo PRO™*). Additional applications include antibody/protein analysis, chiral separations and amino acid analysis. A full line of reagents and buffers are available for performing pK_a and log P measurements, oligonucleotide purity analysis, and protein or dsDNA sizing. Detailed information regarding CombiSep's products and technology can be found at: www.combisep.com.

-- end --